ClinicalTrials.gg
CompletedNCT04900675BLISSUpdated Jun 26, 2025

Bright Light Intervention to Reduce Students' Stress

An interventional study of Bright light intervention and Reddish placebo light in Psychological Stress, Physiological Stress and Sleep Disorders, Circadian Rhythm, sponsored by Universitaet Innsbruck. Completed at 1 site in Austria. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Universitaet Innsbruck · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2020, registered Apr 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Stress, Psychological with a site in Austria — 1 open to participants now, 1 under way, none of them phase 3. Stress, Psychological · Austria.

Started
2020
the only one that year
No phase
8 of 11
1 open now
Registered
5th of 11
by date
Lead sponsor
1 of 11
Universitaet Innsbruck

Among the 11 studies in Stress, Psychological with a site in Austria, this one is the only one that started in 2020, is one of 8 with no phase, and was the 5th registered.

Stress, Psychological

854 studies on the registry are indexed under Stress, Psychological; 141 are open to participants now.

Browse Stress, Psychological studies →

Open to participants now

1 of the 11 studies in Stress, Psychological with a site in Austria is open now. Recruiting first, the newest first:

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 74 Stress, Psychological studies recruiting now, 34 (46%) set no upper age limit and 36 (49%) stop at 75 or younger; 13 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stress, Psychological with a site in Austria, or all of them as a file.
02

Study summary

Increased stress levels are a significant problem for many students and represent a risk factor for impaired mental and physical health as well as academic performance. Stress levels are particularly high during the preparation phase for major exams.

There is good evidence that light therapy is an effective treatment option to improve mood in affective disorders.

The present study aims at investigating the psychophysiological effects of a 3-week morning bright light exposure in reducing stress and stress-related problems in students preparing for major exams.

Read the detailed description

Increased students' stress represents a significant risk factor for impaired mental and physical health as well as academic performance. The World Mental Health Survey (WHO) reports a 12-month prevalence of mental illness of 20.3% among students, with anxiety disorders (14.7%), affective disorders (9.9%), and substance abuse (6.7%) being particularly prominent. Moreover, six out of 10 students suffer from impaired sleep quality.

Offering an effective treatment for stress-related symptoms in students is a challenge. In situations of intense stress, conventional methods such as relaxation and mindfulness-based programs often fail because of poor prior practice. Only a few students apply cognitive behavioral interventions. Although medication might decrease stress symptoms within days, the side effects of drugs cannot be ignored. Therefore, there is a need for effective and efficient treatment of acute stress symptoms in students.

Bright light therapy is an effective treatment for several mental disorders, e.g. affective disorders and sleep disorders. There is some evidence, that exposure to bright light may even reduce stress in patients with burnout symptoms. Thus, exposure to bright light may be a promising new option to reduce academic stress and improve mood and sleep parameters.

In the present study, a large-area desk lamp, which emits diffuse light and is controllable in its luminance and correlated color temperature is used. Study participants are randomly assigned to one of three study arms: (i) exposure to polychromatic light of 5,000 lux and 5,300 Kelvin, (ii) exposure to polychromatic light of 50 lux and 2,200 Kelvin, or (iii) no light intervention. Data collection takes place in winter periods.

03

Conditions studied

  • Psychological Stress
  • Physiological Stress
  • Sleep Disorders, Circadian Rhythm

Keywords

  • stress
  • light therapy
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • students from the faculty of medicine, pharmacy, and law
  • major exam at least 5 weeks ahead
  • major depressive disorder (PHQ-9): Score > 4
  • possession of smartphone and data plan

Exclusion criteria

Exclusion Criteria:

  • suicidal ideation (BDI, Item i): Rating > 1
  • seasonal affective disorder (PIDS-A): Score > 11
  • taking medication which increases photo-sensitivity
  • taking medication to increase cognitive performance
  • starting or changing pharmacotherapy for affective disorders and anxiety disorders within the last two weeks
  • changing of all kinds of medication within the last two weeks
  • headache (PHQ-D, Item f): Rating "severly impaired"
  • increased light sensitivity: Item "Wearing sunglasses outside on sunny days" is answered with 'often' or 'very often'
  • currently undergoing psychotherapeutic treatment
  • the presence of an eye disease for which light therapy is
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    bright white light intervention

    exposure to 5,000 lux with polychromatic white light with 5,300 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks

    Other: Bright light intervention

  • Placebo comparator
    dim reddish light intervention

    exposure to 50 lux with polychromatic reddish light with 2,200 Kelvin at eye level; light exposure starts immediately after awakening; light exposure takes place on weekdays (Monday till Friday) over a period of 3 weeks

    Other: Reddish placebo light

  • No intervention
    no light intervention

    no light intervention takes place in the morning; the study participants follow their natural rhythm of life

Interventions

  • OtherBright light intervention

    Exposure with 5,000 lux at eye level for one hour and a Correlated Color Temperature of 5,300 Kelvin every morning for three weeks.

  • OtherReddish placebo light

    Exposure with 50 lux at eye level for one hour and a Correlated Color Temperature of 2,200 Kelvin every morning for three weeks.

06

What researchers measure

Primary outcomes

  1. subjective stress level - baseline/post

    Perceived Stress Scale (PSS-10); scale: PSS-10 sum score; range:0 - 40; higher scores mean a higher subjective stress level

    Time frame: Change from baseline PSS-10 sum score at the end of week 3

  2. subjective stress level - baseline/post

    Perceived Stress Questionnaire (PSQ-20); scale: PSQ-20 sum score; range: 20 - 80; higher scores mean a higher subjective stress level

    Time frame: Change from baseline PSQ-20 sum score at the end of week 3

  3. subjective stress level - on weekdays

    Perceived Stress Questionnaire (PSQ-20); scale: PSQ-20 sum score; range: 20 - 80; higher scores mean a higher subjective stress level

    Time frame: Change of daily PSQ-20 sum score at each weekday during the light intervention period up to 3 weeks

Secondary outcomes

  1. anxiety

    State-Trait Anxiety Inventory (STAI - form Y) - 20 trait items; scale: STAI-trait sum score; range: 20 - 80; higher scores mean a higher subjective anxiety level

    Time frame: Change from baseline STAI-trait sum score at the end of week 3

  2. mood

    Center for Epidemiologic Studies Depression Scale (CES--D); scale: CES-D sum score; range: 0 - 60; higher scores mean a higher subjective depression level

    Time frame: Change from baseline CES-D sum score at the end of week 3

  3. sleep quality

    Pittsburgh Sleep Quality Index (PSQI); scale: global PSQI score; range: 0 - 21; higher scores mean a lower subjective sleep quality

    Time frame: Change from baseline global PSQI score at the end of week 3

  4. sleep quality - total sleep time

    Wrist actimetry to measure daily total sleep time (TST); scale: sleep duration; range: \>0 (minutes); higher TST means longer sleep period

    Time frame: Change of TST at each night during the light intervention period up to 3 weeks

  5. sleep quality - sleep onset latency

    Wrist actimetry to measure daily sleep onset latency (SOL); scale: duration to fall asleep; range: \>0 (minutes); higher SOL means longer period to fall asleep

    Time frame: change of SOL at each night during the light intervention period up to 3 weeks

  6. sleep quality - wake after sleep onset

    Wrist actimetry to measure daily wake after sleep onset (WASO); scale: duration of being awake during sleep period; range: greater than or equal to 0 (minutes); higher WASO means longer wake periods after sleep onset

    Time frame: change of WASO at each night during the light intervention period up to 3 weeks

  7. sleep quality - sleep efficiency

    Wrist actimetry to measure daily sleep efficiency (SE); scale: percentage; range: 0 - 100; higher SE means a higher undisturbed sleep

    Time frame: change of SE at each night during the light intervention period up to 3 weeks

  8. circadian rest/activity rhythm - interdaily stability

    Circadian rest-activity cycle parameter interdaily stability (IS) derived from weekly wrist actimetry data; scale: real number; range: 0 -1; higher IS means a higher stability in daily rest-activity cycles

    Time frame: change of IV at each of the three light intervention weeks up to 3 weeks

  9. circadian rest/activity rhythm - intradaily variability

    Circadian rest-activity cycle parameter intradaily variability (IV) derived from averaged wrist actimetry data over a period of 1 week; scale: real number; range: 0 - 2; higher IV means a higher variability in 24-h rest-activity cycle

    Time frame: change of IS at each of the three light intervention weeks up to 3 weeks

  10. physiological stress reaction

    cortisol level measured from hair sample; scale: real number (pg/mg); range: \>0; higher hair cortisol level means higher physiological stress

    Time frame: Change from baseline hair cortisol level at the end of week 3

  11. adverse effects - short-term

    astenopic complaints measured with 12 items; scale: sum score; range: 10 - 60; higher sum score means more astenopic complaints

    Time frame: day 5

  12. adverse effects - long-term

    astenopic complaints scale measured with 12 items: sum score; range: 10 - 60; higher sum score means more astenopic complaints

    Time frame: day 15

Other outcomes

  1. resilience

    Resilience Scale (RS-11); scale: RS-11 sum score; range: 11 - 77; higher RS-11 sum score means more perceived resilience

    Time frame: Change from baseline RS-11 sum score at the end of week 3

  2. stress coping

    Coping Inventory for Stressful Situations (CISS) - 24 items; three-dimensional CISS scale: (a) task-oriented coping; (b) emotion-oriented coping, and (c) avoidance-oriented coping; range for each dimension: 8 - 40; higher score in each dimension means higher preference for particular stress coping style

    Time frame: Change from baseline multidimensional CISS scale at the end of week 3

  3. learning strategies

    Learning Strategies of University Students (LIST-K) - 36 items; multidimensional LIST-K scale: 13 subscales; range for each dimension: 3 - 15; higher score in each dimension means higher preference for particular learning strategy

    Time frame: Change from baseline multidimensional LIST-K scale at the end of week 3

  4. psychological distress

    Brief Symptom Inventory (BSI-18); scale: BSI-18 sum score; range: 18 - 90; higher BSI-18 sum score means higher psychological distress

    Time frame: Change from baseline BSI-18 overall score at the end of week 3

  5. somatic symptoms

    The somatic symptom scale (SSS-8); scale: SSS-8 sum score; range: 0 - 32; higher SSS-8 sum score means higher somatic complaints

    Time frame: Change from baseline SSS-8 sum score at the end of week 3

  6. satisfaction with light intervention - short-term

    2 items: (a) recommendation of light intervention to a friend and (b) follow-up usage of light intervention for own purposes; scale: binary score ('yes', 'no'); range: 0 - 1; higher binary scores indicate recommendation and follow-up usage of the light intervention

    Time frame: day 5

  7. satisfaction with light intervention - long-term

    2 items: (a) recommendation of light intervention to a friend and (b) follow-up usage of light intervention for own purposes; scale: binary score ('yes', 'no'); range: 0 - 1; higher binary scores indicate recommendation and follow-up usage of the light intervention

    Time frame: day 15

  8. daily mood state

    Positive and Negative Affect Schedule (PANAS); two-dimensional PANAS scale: sum score for positive and negative mood state; range for each dimension: 10 - 50; higher PANAS scores mean higher positive and negative mood state, respectively

    Time frame: changes from before the light intervention of the two-dimensional PANAS scale at the end of light intervention at each weekday during the light intervention period up to 3 weeks

  9. weekly social rhythms

    The Social Rhythm Metric (SRM) measures the regularity in the occurance of 17 daily events; scale: SRM score; range: 0 - 7; higher SRM scores mean more regular occurance of daily events

    Time frame: changes in SRM scores in week 1, week 2, and week 3

  10. anxiety state

    State-Trait Anxiety Inventory (STAI - form Y) - 20 state items; scale: STAI-state sum score; range: 20 - 80; higher scores mean a higher subjective current anxiety level

    Time frame: changes from before the light intervention STAI-state sum score at the end of light intervention in week 1, week 2, and week 3

  11. cognitive performance

    The Number Letter Task (NLT) measures task switching performance; scale: number of correct answers; range: integer greater than or equal to 0; higher NLT scores means a better task switching performance

    Time frame: changes from before the light intervention NLT number of correct answers at the end of light intervention in week 1, week 2, and week 3

  12. exam anxiety

    German Test Anxiety Inventory (PAF); four-dimensional PAF scale: (a) excitement, (b) concern, (c) interference, and (d) lack of confidence; range for each dimension: 5 - 20; higher scale means higher test anxiety in the corresponding dimension

    Time frame: changes of multidimensional PAF scale at week 1, week 2, and week 3

07

Study locations

1 site
  • University of Innsbruck
    Innsbruck, Tyrol 6020, Austria
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Mar 2024, 41 months.

Of 462 non-industry interventional studies with no phase under Stress, Psychological, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 41 months is above that.

Counting every sponsor, half of 475 studies reached it within 13 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
May 25, 2021
StartActual
Oct 1, 2020
Primary completionActual
Mar 31, 2024
CompletionActual
Oct 31, 2024
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04900675
Lead sponsor
Universitaet Innsbruck
Collaborators
Bartenbach GmbH
Responsible party
Markus Canazei (Principal Investigator, Universitaet Innsbruck) — Principal investigator
First posted
May 25, 2021
Start date
Oct 1, 2020
Primary completion
Mar 31, 2024
Completion
Oct 31, 2024
Last update
Jun 26, 2025

Study contacts

Markus Canazei, PhD
principal investigator · University of Innsbruck

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion